Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) P/B ratio
As of 16 October 2026, Danaher Corporation (DHR) trades at a P/B ratio of 3.1×. Over the past ten years it has ranged from 1.6× (September 2015) to 5.3× (September 2021); the current reading is higher than 57% of that period. That is in line with the Diagnostics & Research industry median of 3.1× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 3.1× | (8.31%) |
| FY2024 | 3.4× | 4.75% |
| FY2023 | 3.2× | (7.15%) |
| FY2022 | 3.5× | (29.99%) |
| FY2021 | 5.0× | 30.56% |
| FY2020 | 3.8× | 12.31% |
| FY2019 | 3.4× | 49.48% |
| FY2018 | 2.3× | 4.93% |
| FY2017 | 2.2× | 3.37% |
| FY2016 | 2.1× | 14.06% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 2.6× | 0.79% |
| Mar 2026 | 2.5× | (18.38%) |
| Dec 2025 | 3.1× | 12.57% |
| Sep 2025 | 2.8× | 2.01% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| WAT Waters Corporation compare | 2.8× |
| DHR Danaher Corporation | 3.1× |
| TMO Thermo Fisher Scientific Inc. compare | 4.9× |
| A Agilent Technologies, Inc. compare | 6.6× |
| IQV IQVIA Holdings Inc. compare | 7.0× |
| ILMN Illumina, Inc. compare | 13.9× |
| IDXX IDEXX Laboratories, Inc. compare | 27.4× |
| NTRA Natera, Inc. compare | 30.8× |
| MTD Mettler-Toledo International, Inc. compare | 2,546× |
| Diagnostics & Research industry median | 3.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement